Low hepcidin triggers hepatic iron accumulation in patients with hepatitis C

Nephrology Dialysis Transplantation

Volumn 29, Issue 6, 2014, Pages 1141-1144

  Hörl, Walter H ^a   Schmidt, Alice ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

hepatitis C; hepcidin; iron; liver

Indexed keywords

ANTIVIRUS AGENT; CCAAT ENHANCER BINDING PROTEIN ALPHA; EPIDERMAL GROWTH FACTOR; HEPCIDIN; IRON; PROHEPCIDIN; SCATTER FACTOR;

BIOACCUMULATION; DISEASE ASSOCIATION; DOWN REGULATION; DRUG EFFECT; HEMODIALYSIS; HEPATITIS C; HUMAN; IRON DEPLETION; IRON METABOLISM; IRON OVERLOAD; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN SYNTHESIS INHIBITION; REVIEW; RISK FACTOR;

HEPATITIS C; HEPCIDIN; IRON; LIVER;

ADULT; ANIMALS; ANTIMICROBIAL CATIONIC PEPTIDES; ANTIVIRAL AGENTS; EPIDERMAL GROWTH FACTOR; FEMALE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HEPATOCYTE GROWTH FACTOR; HEPCIDINS; HUMANS; INTERFERON-ALPHA; IRON; IRON OVERLOAD; LIVER CIRRHOSIS; MALE; MIDDLE AGED; PHLEBOTOMY; RENAL INSUFFICIENCY, CHRONIC; RIBAVIRIN; VIRUS REPLICATION;

EID: 84901752244     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gft467     Document Type: Review

References (44)

1. Shepard CW, Finelli L, Alter MJ. Global epidemiology of hepatitis C virus infection. Lancet Infect Dis 2005; 5: 558-567 (Pubitemid 41196755)
2. Bialek SR, Terrault NA. The changing epidemiology and natural history of hepatitis C virus infection. Clin Liver Dis 2006; 10: 697-715 (Pubitemid 44880154)
3. Fattovich G, Stroffolini T, Zagni I et al. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology 2004; 127(Suppl. 1): S35-S50 (Pubitemid 39423368)
4. Meyers CM, Seeff LB, Stehman-Breen CO et al. Hepatitis C and renal disease: an update. Am J Kidney Dis 2003; 42: 631-657 (Pubitemid 37187365)
5. Batty DS, Jr, Swanson SJ, Kirk AD et al. Hepatitis C virus seropositivity at the time of renal transplantation in the United States: associated factors and patient survival. Am J Transplant 2001; 1: 179-184 (Pubitemid 33674159)
6. Schneeberger PM, Keur I, van Loon AM et al. The prevalence and incidence of hepatitis C virus infections among dialysis patients in the Netherlands: a nationwide prospective study. J Infect Dis 2000; 182: 1291-1299
7. Beinker NK, Voigt MD, Arendse M et al. Threshold effect of liver iron content on hepatic inflammation and fibrosis in hepatitis B and C. J Hepatol 1996; 25: 633-638 (Pubitemid 26373878)
8. Chapoutot C, Esslimani M, Joomaye Z et al. Liver iron excess in patients with hepatocellular carcinoma developed on viral C cirrhosis. Gut 2000; 46: 711-714 (Pubitemid 30305791)
9. Angelucci E, Muretto P, Nicolucci A et al. Effects of iron overload and hepatitis C virus positivity in determining progression of liver fibrosis in thalassemia following bone marrow transplantation. Blood 2002; 100: 17-21 (Pubitemid 35177422)
10. Olynyk JK, Reddy KR, Di Bisceglie AM et al. Hepatic iron concentration as a predictor of response to interferon alfa therapy in chronic hepatitis C. Gastroenterology 1995; 108: 1104-1109
11. Di Bisceglie AM, Bonkovsky HL, Chopra S et al. Iron reduction as an adjuvant to interferon therapy in patients with chronic hepatitis C who have previously not responded to interferon: a multicenter, prospective, randomized, controlled trial. Hepatology 2000; 32: 135-138 (Pubitemid 30432378)
12. Kawamura Y, Akuta N, Sezaki H et al. Determinants of serum ALT normalization after phlebotomy in patients with chronic hepatitis C infection. J Gastroenterol 2005; 40: 901-906 (Pubitemid 41511532)
13. Kageyama F, Kobayashi Y, Kawasaki T et al. Successful interferon therapy reverses enhanced hepatic iron accumulation and lipid peroxidation in chronic hepatitis C. Am J Gasteroenterol 2000; 95: 1041-1050 (Pubitemid 30196744)
14. Fontana RJ, Israel J, LeClair P et al. Iron reduction before and during interferon therapy of chronic hepatitis C: results of a multicenter, randomized, controlled trial. Hepatology 2000; 31: 730-736 (Pubitemid 30118643)
15. Piperno A. Iron stores, response to alpha-interferon therapy, and effects of iron depletion in chronic hepatitis C. Liver 1996; 16: 248-254 (Pubitemid 26290234)
16. Fargion S, Fracanzani AL, Rossini A et al. Iron reduction and sustained response to interferon-alpha therapy in patients with chronic hepatitis C: results of an Italian multicenter randomized study. Am J Gastroenterol 2002; 97: 204-1210
17. Kato J, Kobune M, Nakamura T et al. Normalization of elevated hepatic 8- hydroxy-20-deoxyguanosine levels in chronic hepatitis C patients by phlebotomy and low iron diet. Cancer Res 2001; 61: 8697-8702 (Pubitemid 34013879)
18. Tsuchiya K, Nitta K. Hepcidin is a potential regulator of iron status in chronic kidney disease. Ther Apher Dial 2013; 17: 1-8
19. Zumrutdal A, Sezgin N. The relationship between anemia, liver disease, and hepcidin levels in hemodialysis patients with hepatitis. Indian J Nephrol 2012; 22: 415-418
20. Deicher R, Hörl WH. New insights into the regulation of iron homeostasis. Eur J Clin Invest 2006; 36: 301-309
21. Nishina S, Hino K, Korenaga M et al. Hepatitis C virus-induced reactive oxygen species raise hepatic iron level in mice by reducing hepcidin transcription. Gastroenterology 2008; 134: 226-238 (Pubitemid 350309316)
22. Miura K, Taura K, Kodama Y et al. Hepatitis C virus-induced oxidative stress suppresses hepcidin expression through increased histone deacetylase activity. Hepatology 2008; 48: 1420-1429
23. Girelli D, Pasino M, Goodnough JB et al. Reduced serum hepcidin levels in patients with chronic hepatitis C. J Hepatol 2009; 51: 845-852
24. Tsochatzis E, Papatheodoridis GV, Koliaraki V et al. Serum hepcidin levels are related to the severity of liver histological lesions in chronic hepatitis C. J Viral Hepat 2010; 17: 800-806
25. Fujita N, Sugimoto R, TakeoMet al. Hepcidin expression in the liver: relative low level in patients with chronic hepatitis C. Mol Med 2007; 13: 97-104 (Pubitemid 46786838)
26. Lambrecht RW, Sterling RK, Naishadham D et al. Iron levels in hepatocytes and portal tract cells predict progression and outcomes of patients with advanced chronic hepatitis C. Gastroenterology 2011; 140: 1490-1500
27. Feld JJ, Hoofnagle JH. Mechanism of action of interferon and ribavirin in treatment of hepatitis C. Nature 2005; 436: 967-972 (Pubitemid 41191673)
28. Ryan JD, Altamura S, Devitt E et al. Pegylated interferon-α induced hypoferremia is associated with the immediate response to treatment in hepatitis C. Hepatology 2012; 56: 492-500
29. Sugimoto R, Fujita N, Tomosugi N et al. Impaired regulation of serum hepcidin during phlebotomy in patients with chronic hepatitis C. Hepatology Res 2009; 39: 619-624
30. Mitsuyoshi H, Yasuik K, Yamaguchi K et al. Pathogenic role of iron deposition in reticuloendothelial cells during the development of chronic hepatitis C. Int J Hepatol 2013 [Epub 4 April]
31. Goodnough JB, Ramos E, Nemeth E et al. Inhibition of hepcidin transcription by growth factors. Hepatology 2012; 56: 291-299
32. Babitt JL, Huang FW, Xia Y et al. Modulation of bone morphogenetic protein signaling in vivo regulates systemic iron balance. J Clin Invest 2007; 117: 1933-1939 (Pubitemid 47036327)
33. Furanti T, Hino K, Okuda M et al. Hepatic iron overload induces hepatocellular carcinoma in transgenic mice expressing the hepatitis C virus polyprotein. Gastroenterology 2006; 130: 2087-2098 (Pubitemid 43816966)
34. Courselaud B. C/EBPalpha regulates hepatic transcription of hepcidin, an antimicrobial peptide and regulator of iron metabolism. cross-talk between C/EBP pathway and iron metabolism. J Biol Chem 2002; 277: 41163-41170 (Pubitemid 35215708)
35. Trinder D, Ayonrinde OT, Olynyk JK. HCV, iron, and oxidative stress: the new choreography of hepcidin. Gastroenterology 2008; 134: 348-351 (Pubitemid 350309353)
36. Kotta-Loizou I, Vassilaki N, Pissas G et al. Hepatitis C virus core + 1/ARF protein decreases hepcidin transcription through an AP1 binding site. J Gen Virol 2013; 94: 1528-1534
37. Okada S. Iron-induced tissue damage and cancer: the role of reactive species-free radicals. Pathol Int 1996; 46: 311-332 (Pubitemid 26230953)
38. Pietrangelo A. Hereditary hemochromatosis-a new look at an old disease. N Engl J Med 2004; 350: 2383-2397
39. Le NT, Richardson DR. The role of iron in cell cycle progression and the proliferation of neoplastic cells. Biochim Biophys Acta 2002; 1603: 31-46 (Pubitemid 35257983)
40. Harrison-Findik DD, Schafer D, Klein E et al. Alcohol metabolismmediated oxidative stress down-regulates hepcidin transcription and leads to increased duodenal iron transporter expression. J Biol Chem 2006; 281: 22974-22982
41. Liu H, Trinh TL, Dong H et al. Iron regulator hepcidin exhibits antiviral activity against hepatitis C virus. PLOS One 2012; 7: e46631
42. Nagashima M, Kudo M, Chung H et al. Regulatory failure of serum prohepcidin levels in patients with hepatitis C. Hepatol Res 2006; 36: 288-293 (Pubitemid 44718431)
43. Caliskan Y, Yelken B, Ozkok A et al. Lower serum prohepcidin levels associated with lower iron and erythropoietin requirements in hemodialysis patients with chronic hepatitis C. BMC Nephrol 2012; 13: 56
44. Costa E, Swinkels DW, Laarakkers CM et al. Hepcidin serum levels and resistance to recombinant human erythropoietin therapy in haemodialysis patients. Acta Haematol 2009; 122: 226-229